iRadimed Corporation $IRMD Holdings Lowered by Nine Ten Capital Management LLC

Posted by Stanley Muller on Sep 9th, 2026

Nine Ten Capital Management LLC decreased its position in shares of iRadimed Corporation (NASDAQ:IRMD – Free Report) by 23.3% during the second quarter, Holdings Channel.com reports. The firm owned 256,562 shares of the medical equipment provider’s stock after selling 77,926 shares during the period. iRadimed comprises 7.6% of Nine Ten Capital Management LLC’s investment portfolio, making the stock its 6th biggest holding. Nine Ten Capital Management LLC’s holdings in iRadimed were worth $24,517,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of iRadimed in the second quarter valued at approximately $92,485,000. California State Teachers Retirement System lifted its position in shares of iRadimed by 12,018.2% during the 2nd quarter. California State Teachers Retirement System now owns 954,549 shares of the medical equipment provider’s stock valued at $91,217,000 after buying an additional 946,672 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after acquiring an additional 205,783 shares during the period. Ranger Investment Management L.P. acquired a new stake in iRadimed in the 2nd quarter valued at $9,398,000. Finally, Bank of New York Mellon Corp purchased a new stake in iRadimed in the 2nd quarter worth $7,252,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 34.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, iRadimed has a consensus rating of “Moderate Buy” and an average price target of $120.00.

View Our Latest Analysis on IRMD

iRadimed Price Performance

IRMD stock opened at $84.40 on Wednesday. The business has a 50 day simple moving average of $91.77 and a 200-day simple moving average of $93.37. The firm has a market capitalization of $1.08 billion, a PE ratio of 47.15 and a beta of 0.89. iRadimed Corporation has a 1 year low of $67.84 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The firm had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities research analysts expect that iRadimed Corporation will post 1.98 EPS for the current year.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is presently 44.69%.

iRadimed Profile

(Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.